Freeman-Gallant, G. | Search bioRxiv

bioRxiv2024

A type-specific B cell epitope at the apex of Outer surface protein C (OspC) of the Lyme disease spirochete, Borreliella burgdorferi

Broadly protective immunity to the Lyme disease spirochete, Borreliella burgdorferi, is constrained by an overwhelming antibody response against type-specific epitopes on Outer surface protein C (OspC), a homodimeric helix-rich lipoprotein essential for early stages of spirochete dissemination in vertebrate hosts. However, the molecular basis for type-specific immunity has not been fully elucidated. In this report, we produced and characterized an OspC mouse monoclonal antibody, 8C1, that recognizes native and recombinant OspC type A (OspCA) but not OspC types B or K, and arrests B. burgdorferi motility independent of complement. Epitope mapping by HDX-MS localized 8C1s epitope to a protruding ridge on the apex of OspCA -helix 3 (residues 130-150) previously known to be an immunodominant region of the molecule. Alanine scanning pinpointed 8C1s core binding motif to a solvent exposed patch consisting of residues K141 H142 T143 D144. In parallel, analysis of 26 Lyme disease positive serum samples confirmed antibody reactivity with this region of OspCA, with residues E140 and D144 as being most consequential. Our results underscore the importance of -helix 3 as a target of type-specific epitopes on OspCA across mice and humans that should be taken into consideration in Lyme disease vaccine design.

immunology↗

bioRxiv2024

A refined human linear B cell epitope map of Outer surface protein C (OspC) from the Lyme disease spirochete, Borreliella burgdorferi

A detailed understanding of the human antibody response to Outer surface protein C (OspC) of Borrelellia burgdorferi has important implications for Lyme disease diagnostics and vaccines. In this report, a total of 13 peptides encompassing eight reported OspC linear B cell epitopes from OspC types A, B and K, including the conserved C-terminus (residues 193-210: peptide C10), were evaluated by multiplex immunoassay (MIA) for IgG reactivity with [~]700 human serum samples confirmed positive in a two-tiered Lyme disease diagnostic assay and [~]160 post-treatment Lyme disease (PTLD) serum samples. The VlsE C6-17 peptide was included as a positive control. Diagnostic serum IgG reacted with 11 of the 13 OspC-derived peptides, significantly more than controls, with the C10 peptide being the most reactive. In the PTLD serum samples, two OspC peptides including C10 were significantly more reactive than controls. Spearmans rank correlation matrices and hierarchical clustering indicated a strong correlation between C10 and VlsE C6-17 peptide reactivity but little demonstrable association between C10 and the other OspC peptides or recombinant OspC. OspC peptide reactivities (excluding C10) were strongly correlated with each other and were disproportionately influenced by a subset of pan-reactive samples. In the PTLD cohort, C10 clustered with the other OspC-derived peptides and was distinct from OspC and VlsE C6-17. The asynchronous serologic response to OspC, C10, and the OspC-derived peptides reveals the complexity of B cell responses to B. burgdorferi and confounds simple interpretation of antibody profiles associated with Lyme disease. IMPORTANCELyme disease is an emerging tick-borne infection caused by the spirochete, Borreliella burgdorferi. In humans, antibodies against spirochetal outer surface lipoproteins are proposed to play a role in disease resolution and in protection against reinfection. Some of those same antibodies also serve as diagnostic indicators of an active or history of Lyme disease. In this study, we sought to validate reported antibody binding sites on Outer surface protein C (OspC), a known target of both protective and diagnostic antibodies.

immunology↗